Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cremin Complex is a combination pharmaceutical preparation developed by Shanghai Sixth People's Hospital for the treatment of attention deficit hyperactivity disorder (ADHD). The formulation consists of clemastine, an H1-receptor antagonist, along with vitamin B6 (pyridoxine) and glutamic acid. Clemastine is included for its sedative properties and its ability to cross the blood-brain barrier, which was historically utilized in China to manage symptoms of hyperactivity and impulsivity in pediatric patients. Vitamin B6 acts as a cofactor in the synthesis of essential neurotransmitters such as dopamine, serotonin, and GABA, while glutamic acid serves as a metabolic support for brain function. Although once a common hospital-made preparation (医院制剂) in Shanghai during the late 20th century, its use has largely been superseded by more targeted ADHD medications like methylphenidate and atomoxetine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cremin Complex.